Diabetes is classified under 2 main types:
Individuals with diabetes have an increased risk of developing a number of serious health problems. Consistently high blood glucose levels can lead to irreversible complications affecting the heart and blood vessels, eyes, kidneys, nerves and teeth. In addition, people with diabetes also have a higher risk of developing infections.
Diabetes is a leading cause of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
Approximately 463 million adults (between 20-79 years of age) are living with diabetes; by 2045 this will rise to 700 million(1).
Diabetes is identified by testing the blood sugar. This is achieved by measuring the concentration of the glucose by different analytical tests: mainly FPG (Fasting Plasma Glucose) and OGTT (Oral Glucose Tolerance test) or by measuring a specific fraction of glycated hemoglobin (HbA1c) from patient whole blood sampling.
Hb A1c, is defined as the hemoglobin A which is irreversibly glycated at one or both N-terminal valines of the beta chain. It is a widely used biomarker in diabetes management, has a greater pre-analytical stability compared to glucose and does not require the patient to fast prior to testing. It also provides information on the monitoring of long-term glycemic control and an assessment of the risk of developing complications.
Furthermore Hb A1c is a standardised parameter by the IFCC (International Federation of Clinical Chemistry) in harmony with the NGSP network.
Capillary electrophoresis is the next generation separation method that provides clear-cut and precise separation of the Hb A1c fraction with no altered results in the presence of the most frequent interferences (labile A1c, carbamylated Hb, Hb F, heterozygous S, C, D and E). The high-resolution power of the method allows the incidental detection of homozygous hemoglobin variants (sickle cell disease…) preventing HbA1c reporting in the absence of Hb A.
Hemoglobin C, D Punjab, E or S trait can interfere with hemoglobin A1c (HbA1c) results depending on the method of analysis used. Therefore, it is important to know the limitations of the method used for HbA1c determination.
This article reminds the reader of the importance of detecting the Hb variants when measuring HbA1c for the labs and clinicians to better interpret the results and to ensure optimal management of the diabetic patient.
The EurA1c trial, organized yearly, investigates the performance of HbA1c assays across countries and manufacturers.
With this short video report, become aware of all the benefits of partnering with Sebia and integrate your capillary electrophoresis into the lab track automation.
Educational Webinar with Dr. Cas WEYKAMP
Educational Webinar with David G. Grenache, PhD, D(ABCC)
Chief Scientific Officer, TriCore Reference Laboratories
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
IFCC Euromedlab /WorldLab 2023
Sebia booth: #21
Sebia Workshop: EduW15
Evolution makes the difference.
The power of up to 36 capillaries in one automated high volume workcell.
Connect our flexible electrophoresis instrument on lab automation track.
The compact and affordable automation of Capillary Electrophoresis.
Uncompromized HbA1c Results.
(1) IDF DIABETES ATLAS – 9th edition 2019: https://www.diabetesatlas.org/
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.